Clinical trial NCT06997796: Treatment of Nosebleeds in the Emergency Department With Powder Tranexamic Acid
Official title: Sprayed-In Medicated Powder for Less-Invasive Epistaxis Treatment Using Tranexamic Acid: The Bloody SIMPLE Treatment Pilot Study
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: PHASE1
PHASE2
Conditions: Epistaxis Nosebleed
Lead sponsor: Peterborough Regional Health Centre
Sponsor class: OTHER
Collaborators: name: University of Ottawa
First posted: 2025-05-30
Enrollment: 24
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Nosebleeds are very common, occurring in 60% of the population; in some patients, nosebleeds are a life-threatening emergency. To stop a nosebleed in the emergency department, doctors usually have to burn the nose (called cauterization) or insert pledgets (called nasal packing) into the nose to apply direct pressure to the bleeding site. Nasal packing can cause pain and discomfort at the time it is inserted in the nose and again when it is removed. In rare cases it can cause a range of complications: minor complications include scar bands in the nose, but serious complications of nasal packing have also occurred, including death. Nasal packing can also present risks to doctors, such as the risk of contracting airborne and bloodborne infections, like COVID-19 and HIV.

Tranexamic acid in pill form or given directly into a vein is a medication that is currently used for nosebleeds. This study looks to evaluate if tranexamic acid in powder form sprayed directly in the nose can be used as an alternative to cauterization or nasal packing for the treatment of nosebleeds.


Eligibility criteria: Inclusion Criteria:

* Capable of giving informed consent form
* Stated willingness to comply with all study procedures and availability for the duration of the study
* Adults 18 years or older
* Male or female
* Presenting to the ED with active, spontaneous epistaxis. Anterior versus posterior epistaxis will be identified a priori. Anterior epistaxis is operationally defined as active nasal bleeding that occurs anterior to the anterior limit of the middle turbinate, visible by anterior rhinoscopy.

Exclusion Criteria:

* Prior sinonasal surgery within the preceding 1 month.
* Patients who required medical treatment for epistaxis in the preceding 30 days.
* Septum perforation.
* Known history of bleeding disorders, including thrombocytopenia, hemophilia, hereditary hemorrhagic telangiectasia, or von Willebrand disease.
* History of known thromboembolic disease, including subarachnoid hemorrhage, stroke, or TIA.
* Known history of disease of the central nervous system, including seizures, convulsions, or intra-cerebral disease processes/lesions.
* Known or suspected history of significant skull base trauma, including skull base fracture or cerebrospinal fluid leak.
* Known history of acquired disturbances of colour vision.
* Known hematuria or any bleeding related to the kidney.
* Pregnant and/or lactating women.
* History of known allergy or sensitivity to the study medication.
* Presence of signs or symptoms of concomitant emergent conditions, including myocardial infarction, stroke, major trauma, shock, or hemodynamic instability.
* Patients with other medical conditions including cognitive limitations or impairment due to substance abuse.
* Patients with any other condition that, in the opinion of the investigator, may present an unreasonable risk to the patient, may make the patient unreliable, or may interfere with the study assessments.
* Current participation in another interventional clinical trial.

Primary outcomes:
measure: Cessation of epistaxis
timeFrame: Day 1
Secondary outcomes:
measure: Time to cessation of epistaxis
timeFrame: Day 1
measure: Pain of the treatment
timeFrame: Day 1
measure: Total time in the Emergency Department
timeFrame: Day 1
measure: Number of participants who returned to the Emergency Department for treatment of epistaxis
timeFrame: within the first 24 hours and the first 5 days after treatment
Other outcomes:
measure: Age
timeFrame: Day 1
measure: Anticoagulant and/or antiplatelet medication use
timeFrame: Day 1
measure: Type of epistaxis
timeFrame: Day 1
measure: Adverse events and/or patient-reported side effects
timeFrame: up to 3 weeks
measure: Treatment site complications
timeFrame: up to 3 weeks
Locations:
city: Peterborough
country: Canada
facility: Peterborough Regional Health Centre
state: Ontario
Study officials:
affiliation: Peterborough Regional Health Center; University of Ottawa
name: Anne Conlin, Assistant Professor, University of Ottawa, HBA&Sc, MD, FRCSC
role: PRINCIPAL_INVESTIGATOR
References: